Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)

Atrial Fibrillation Clinical Trial

— OPTIMAL  

Official title:

Evaluation of the Precision and Accuracy of International Normalised Ratio (INR) Measurements as Assessed by the LumiraDx Instrument in a Professional Point of Care Setting With Multiple Operators

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03682419
• Other study ID #: D-CLIN-PROT-00001
• Status: Completed
• Phase: N/A
• Start date: September 17, 2018
• Est. completion date: November 23, 2018

Study information

• Verified date: September 2018
• Source: LumiraDx UK Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comparison of capillary whole blood INR determined by LumiraDx Instrument to venous plasma INR determined by laboratory reference method (IL ACL ELITE PRO) for method comparison and assessment of accuracy and bias by regression analysis and other analytical methods.

Description:

A performance evaluation study designed to assess the precision and accuracy of the LumiraDx Instrument, a point of care in vitro diagnostic system employing a portable diagnostic meter in conjunction with single use analyte test strips, for the quantitative determination of Prothrombin Time expressed as International Normalised Ratio (INR), as sampled from individuals evaluated for INR at the point of care (POC).

The accuracy of the LumiraDx Instrument INR results will be assessed by, in the first instance, comparison to the INR results obtained from the same individuals as analysed by trained laboratory professionals using the paired venous plasma samples in the reference device IL ACL ELITE PRO Coagulation Analyzer. The accuracy of INR measurements of capillary whole blood across the range of haematocrit (25% - 55%) will be assessed using paired haematocrit results obtained from the HemoCue Hb 201+ on venous whole blood. The results of these evaluations are intended to be used for regulatory filings for the LumiraDx Instrument and LumiraDx INR test as an in vitro diagnostic test in the European Union (EU) and other relevant geographies. For information only, the accuracy of the LumiraDx Instrument INR Test will also be assessed by comparison to INR results from an alternative point of care instrument, the Roche Coaguchek PRO II.

Adult males and females currently in receipt of vitamin K antagonist therapy will be included on the study. Approximately 500 subjects will be recruited to ensure that sufficient suitable subjects are enrolled and to allow for a small level of exclusions. The power calculation as well as recommendations of the FDA CLIA Waiver Guidance document (1) requires a minimum of 360 valid subjects in total (inclusive of non-therapy subset). A subsection of the subject population (~50 subjects) will consist of adult males and females who fulfil all other study inclusion criteria but are not in receipt of vitamin K antagonist therapy. This will be done in order to test the lower measurement limit of the LumiraDx Instrument INR test. At the end of the study the Healthcare Professional will be asked to complete a User Acceptability Questionnaire which is intended to assess the acceptability of the LumiraDx INR system in terms of ease of use.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 420
• Est. completion date: November 23, 2018
• Est. primary completion date: November 23, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria - VKA Therapy Subjects:

• Persons >18 years of age

• Willing and able to provide written informed consent and comply with study procedures

• Currently prescribed vitamin K antagonist therapy

• Deemed medically appropriate for study participation by the Investigator

Exclusion Criteria - VKA Therapy Subjects:

• Persons <18 years of age

• Subject has previously participated in this study

• Subject is within 4 weeks of first prescription of vitamin K antagonist therapy

• Confirmed or suspected pregnancy

• Unwilling or unable to provide written informed consent and comply with study procedures

• Vulnerable populations deemed inappropriate for study by the Investigator

• Deemed medically inappropriate for study by the Investigator (i.e. patients with a known inherited [e.g. haemophilia or von Willebrand's disease] or acquired [e.g. liver cirrhosis] condition likely to be associated with a coagulopathy; or patients receiving non-VKA anticoagulant medications)

Inclusion Criteria - Non-VKA Therapy Subjects:

• Persons >18 years of age

• Willing and able to provide written informed consent and comply with study procedures

• Deemed medically appropriate for study participation by the Investigator

Exclusion Criteria - Non-VKA Therapy Subjects:

• Persons <18 years of age

• Subject has previously participated in this study

• Confirmed or suspected pregnancy

• Unwilling or unable to provide written informed consent and comply with study procedures

• Vulnerable populations deemed inappropriate for study by the Investigator

• Any persons deemed medically inappropriate for study by the Investigator

Related Conditions & MeSH terms

• Antiphospholipid Syndrome
• Artificial Heart Device User
• Atrial Fibrillation
• Deep Vein Thrombosis
• Embolism
• Infarction
• Myocardial Infarction
• Post-Myocardial Infarction Syndrome
• Pulmonary Embolism
• Syndrome
• Thrombophilia
• Thrombosis
• Venous Thrombosis

Intervention

Procedure:
• VKA Patients
Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy
• Non-VKA Patients
Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy

Locations

Country	Name	City	State
United Kingdom	Glasgow Royal Infirmary Clinical Research Facility	Glasgow
United Kingdom	Golden Jubilee National Hospital	Glasgow
United Kingdom	Wishaw General Hospital, NHS Lanarkshire	Wishaw

Sponsors (1)

Lead Sponsor	Collaborator
LumiraDx UK Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the clinical performance of the LumiraDx instrument	Measurement of INR using Capillary & Venous blood samples	8 weeks
Secondary	To determine the accuracy of the LumiraDx instrument	Measurement of INR & Haematocrit using Capillary & Venous blood samples	8 weeks